Canine urothelial carcinoma: genomically aberrant and comparatively relevant by Shapiro, S. G. et al.
Canine urothelial carcinoma: genomically aberrant and 
comparatively relevant
S. G. Shapiro,
Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina 
State University, 1060 William Moore Drive, Raleigh, NC 27607, USA
S. Raghunath,
Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina 
State University, 1060 William Moore Drive, Raleigh, NC 27607, USA; Department of Pediatrics 
and Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 
84112, USA
C. Williams,
Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina 
State University, 1060 William Moore Drive, Raleigh, NC 27607, USA
A. A. Motsinger-Reif,
Department of Statistics, College of Sciences, North Carolina State University, Raleigh, NC, USA; 
Center for Comparative Medicine and Translational Research, North Carolina State University, 
Raleigh, NC, USA
J. M. Cullen,
Department of Population Health and Pathobiology, College of Veterinary Medicine, North 
Carolina State University, Raleigh, NC, USA; Center for Comparative Medicine and Translational 
Research, North Carolina State University, Raleigh, NC, USA
T. Liu,
Anatomic Pathology Division Department of Pathology, University of Utah, 1950 Circle of Hope, 
RM N3105, Salt Lake City, UT 84112, USA
D. Albertson,
Anatomic Pathology Division Department of Pathology, University of Utah, 1950 Circle of Hope, 
RM N3105, Salt Lake City, UT 84112, USA
M. Ruvolo,
Agilent Technologies, 5301 Stevens Creek Blvd., Santa Clara, CA 95051, USA
A. Bergstrom Lucas,
Agilent Technologies, 5301 Stevens Creek Blvd., Santa Clara, CA 95051, USA
J. Jin,
Agilent Technologies, 5301 Stevens Creek Blvd., Santa Clara, CA 95051, USA
Correspondence to: M. Breen, Matthew_Breen@ncsu.edu.
Electronic supplementary material The online version of this article (doi:10.1007/s10577-015-9471-y) contains supplementary 
material, which is available to authorized users.
HHS Public Access
Author manuscript
Chromosome Res. Author manuscript; available in PMC 2015 July 14.
Published in final edited form as:














Department of Veterinary Clinical Sciences, Purdue University, School of Veterinary Medicine, 
West Lafayette, IN, USA
J. D. Schiffman, and
Department of Pediatrics and Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, 
Salt Lake City, UT 84112, USA
M. Breen
Department of Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina 
State University, 1060 William Moore Drive, Raleigh, NC 27607, USA; Center for Comparative 
Medicine and Translational Research, North Carolina State University, Raleigh, NC, USA; Center 
for Human Health and the Environment, North Carolina State University, Raleigh, NC, USA; 
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
M. Breen: Matthew_Breen@ncsu.edu
Abstract
Urothelial carcinoma (UC), also referred to as transitional cell carcinoma (TCC), is the most 
common bladder malignancy in both human and canine populations. In human UC, numerous 
studies have demonstrated the prevalence of chromosomal imbalances. Although the 
histopathology of the disease is similar in both species, studies evaluating the genomic profile of 
canine UC are lacking, limiting the discovery of key comparative molecular markers associated 
with driving UC pathogenesis. In the present study, we evaluated 31 primary canine UC biopsies 
by oligonucleotide array comparative genomic hybridization (oaCGH). Results highlighted the 
presence of three highly recurrent numerical aberrations: gain of dog chromosome (CFA) 13 and 
36 and loss of CFA 19. Regional gains of CFA 13 and 36 were present in 97% and 84% of cases, 
respectively, and losses on CFA 19 were present in 77% of cases. Fluorescence in situ 
hybridization (FISH), using targeted bacterial artificial chromosome (BAC) clones and custom 
Agilent SureFISH probes, was performed to detect and quantify these regions in paraffin-
embedded biopsy sections and urine-derived urothelial cells. The data indicate that these three 
aberrations are potentially diagnostic of UC. Comparison of our canine oaCGH data with that of 
285 human cases identified a series of shared copy number aberrations. Using an informatics 
approach to interrogate the frequency of copy number aberrations across both species, we 
identified those that had the highest joint probability of association with UC. The most significant 
joint region contained the gene PABPC1, which should be considered further for its role in UC 
progression. In addition, cross-species filtering of genome-wide copy number data highlighted 
several genes as high-profile candidates for further analysis, including CDKN2A, S100A8/9, and 
LRP1B. We propose that these common aberrations are indicative of an evolutionarily conserved 
mechanism of pathogenesis and harbor genes key to urothelial neoplasia, warranting investigation 
for diagnostic, prognostic, and therapeutic applications.
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Urothelial carcinoma (UC) of the bladder, also known as transitional cell carcinoma (TCC), 
is the second most common human urogenital cancer, surpassed only by prostate cancer. In 
2014, an estimated 74,690 UC diagnoses were made in the USA alone, comprising 4–5% of 
all human cancer diagnoses (American Cancer Society 2014). Similarly, UC is the most 
common urogenital cancer of dogs, representing 1.5–2% of canine cancer diagnoses 
annually in the USA (Mutsaers et al. 2003; Oliveira et al. 2014). At diagnosis, 
approximately 20% of canine and 10% of human patients have overt metastasis, with 
microscopic metastases likely present in many more cases (Knapp et al. 2000; Oliveira et al. 
2014). Due to the high metastatic rate and, particularly in canines, delayed diagnosis, the 
identification of potential early diagnostic indicators, including genomic changes, is highly 
desirable.
Previous studies have established that canine UC resembles and behaves similarly to 
invasive human UC, providing a beneficial in vivo model for the disease (Knapp et al. 2000; 
Dhawan et al. 2009). The canine cancer model is an optimal one for human cancers: people 
and their pets share an environment, have similar relative life spans, and develop the disease 
naturally (Shearin and Ostrander 2010). Additionally, bottlenecks in the domestic dog 
population due to tightly controlled breeding have created breeds of dogs with high genetic 
similarity and resultant disease predispositions (Dobson 2013). Scottish Terriers are 20 
times more likely to develop UC than the average dog (Knapp et al. 2014). Other breeds 
with high incidence of UC include Shetland Sheepdogs, Beagles, West Highland White 
Terriers, and Wire Hair Fox Terriers, who are three to five times more likely to develop UC 
than the general dog population. The overwhelming breed predispositions associated with 
canine UC suggest a strong genetic component to disease development. Interspecies 
chromosome syntenty allows us to capitalize on the unique genetic homogeneity of purebred 
dogs to elucidate more specific, evolutionarily conserved, and relevant genomic aberrations 
in humans, regions that may prove clinically relevant to both dogs and people.
In the current study, we evaluated 31 primary canine UC tumor biopsies via genome-wide 
oligonucleotide array comparative genomic hybridization (oaCGH). Validation of CGH data 
was performed using formalin fixed paraffin-embedded (FFPE) UC biopsies (n=5) and urine 
sediments (n=24) via fluorescence in situ hybridization (FISH). A hematoxylin and eosin 
(H&E)-stained slide of each tumor biopsy was evaluated and staged in parallel by human 
and veterinary pathologists. Canine oaCGH data were compared with those derived from 
285 UCs, revealing striking similarities of copy number gains and losses shared between 
species. Additionally, we describe a high-specificity FISH-based method for canine UC 
diagnosis utilizing low-volume, free-catch urine specimens. These data suggest: (1) the 
diagnostic relevance of genomic aberrations in veterinary medicine, (2) a non-invasive 
method of canine UC diagnosis, and (3) the canine model is a valuable model in the study of 
human UC.
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Canine UC case collection
Cystoscopy or cytstotomy specimens were obtained from a series of chemotherapy-naïve, 
client-owned dogs presenting with suspected UC at the veterinary hospitals at Purdue 
University (PU) and North Carolina State University (NCSU). Each biopsy specimen was 
either snap frozen and subsequently stored in liquid nitrogen, or fixed in 10% neutral 
buffered formalin (NBF) for 24 h prior to embedding in paraffin. Histopathological 
evaluation confirmed a diagnosis of UC for all 31 specimens (Table 1). Urine samples 
(n=24) were collected via free catch (1–5 mL) from additional NCSU patients with 
confirmed UC (diagnosis via urine cytology or histopathology) and stored at 4°C for a 
maximum of 24 h until further processing (see below). Control urothelium was collected 
from recently euthanized dogs at necropsy and confirmed to be non-neoplastic by 
histopathologic evaluation. All biopsy and urine specimens were obtained with informed 
client consent and under institutionally approved protocols at PU and NCSU.
Pathologic evaluation of canine UC
H&E-stained slides previously used for canine UC diagnosis were reviewed by a board-
certified veterinary pathologist (JC) and two human genitourinary pathologists (TL, DA). 
Slides were first scanned at low magnification to locate the neoplastic regions of the biopsy. 
Magnification was then increased to allow identification of specific histologic criteria in the 
neoplasms. The urothelial basement membrane was evaluated for evidence of invasion, as 
shown by a clear breech in basement membrane and invasion of the lamina propria of the 
bladder (stage T1). If no such invasion was observed, tumors were classified as either Ta 
(papillary carcinoma) or Tis (in situ “flat tumor”). When the biopsy included deeper layers 
of the bladder wall, the UC was graded on the basis of the extent of invasion of the bladder. 
UC that invaded the muscularis propria were graded as T2, and those that extended into the 
perivesical tissues were graded as T3. Pathologic staging was performed in accordance with 
the World Health Organization (WHO) and American Joint Committee on Cancer (AJCC) 
guidelines (American Joint Committee on Cancer 2002). The compiled pathologic data are 
included in Table 1.
Canine oaCGH
DNA was extracted from biopsy specimens using either the DNeasy Kit (frozen samples, 
Qiagen, Valencia, CA) or QIAamp DNA FFPE Tissue Kit (FFPE samples, Qiagen). DNA 
samples were verified to be of sufficient quantity and integrity by agarose gel 
electrophoresis (>1 kb) and spectrophotometry (260:280 and 260:230 both >1.8). Gender-
specific DNA reference samples were generated from whole blood of healthy mixed-breed 
dogs, pooling equimolar quantities of DNA from ten males or ten females. DNA was labeled 
using the Genomic DNA Enzymatic Labeling Kit (Agilent, Santa Clara, CA), as described 
previously (Poorman et al. 2014; Thomas et al. 2014). Fluorescently labeled test and 
reference samples were hybridized to Canine G3 SurePrint 180,000 feature oaCGH arrays 
(Agilent, AMADID 025522) for 40 h, as described previously (Poorman et al. 2014; 
Thomas et al. 2014). Arrays were scanned at 3 μm (Agilent, Model G2505C); data were 
extracted using Feature Extraction v10.10 software (Agilent Technologies, Santa Clara, CA) 
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and assessed for quality using the Quality Metrics report tool in Agilent's Feature extraction 
software (v10.5) (Agilent Technologies). Raw data were evaluated to identify and exclude 
probes displaying non-uniform hybridization or signal saturation and imported into Nexus 
copy number v7.5 (BioDiscovery, Hawthorne, CA) for analysis. Copy number calls were 
made using the FASST2 segmentation algorithm with a significance threshold of 5.05−6. 
Aberrations were defined as a minimum of three consecutive probes with log2 tumor: 
reference value of >1.14 (high gain), 1.13 to 0.201 (gain), −0.234 to −1.1 (loss), and ≤1.1 
(big loss).
Selection of canine diagnostic regions
Genome-wide oaCGH data for the canine cohort were evaluated to identify chromosomal 
regions that exhibited the highest penetrance of aberrations. To develop a DNA copy 
number-based assay for the detection of neoplastic epithelial transitional cells shed in the 
urine, three regions with the highest frequency of unidirectional aberration in neoplastic 
biopsies were identified and compared with oaCGH data from a cohort of 100 non-
neoplastic DNA specimens. Aberrant regions were classified as gains, losses, or neutral for 
the purposes of classification. Potential predictive model(s) were built using the 
classification tree algorithm J48, as implemented in Weka c3.7 (Hall et al. 2009). The J48 
algorithm was implemented both with and without fivefold cross-validation, in order to 
assess the potential predictive performance. In both cases, the same model (in terms of 
variables selected and tree architecture) resulted, so only the model without cross-validation 
is presented here (for simplicity). Several measures of model fit were calculated, including 
the relative risk, odds ratio, sensitivity, specificity, and overall misclassification rate for each 
of the three regions.
Fluorescence in situ hybridization of canine FFPE biopsies using BAC and custom 
SureFISH probes
To validate oaCGH data, regions on CFA 13, 19, and 36 with >75% aberration frequency 
among patients and one balanced region on CFA 8 (oaCGH Log2=0 in 100% of patients) 
were selected for FISH analysis. Differentially labeled FISH probes for each of these four 
regions were generated using DNA isolated from canine bacterial artificial chromosome 
(BAC) clones of the CHORI-82 canine BAC library (http://bacpac.chori.org/library.php?
id=253)(Table 2). In addition, in silico-selected sequences from non-repetitive canine 
genomic sequences (canfam2) were selected for the three unbalanced regions (segments of 
on CFA 13, 19, and 36) (Table 2) and submitted for massively parallel de novo synthesis 
and generation of custom SureFISH probes (Agilent Technologies), labeled with one of the 
three current color options (red, green, or aqua). Each FISH probe was first assessed to 
verify a unique cytogenetic location when hybridized to canine metaphase spreads and 
interphase nuclei from healthy dogs using protocols reported previously for BACs (Poorman 
et al. 2014) and per the manufacturer's recommendations for SureFISH probes (Agilent 
Technologies).
FISH was performed on 5 μm sections of FFPE biopsy specimens from healthy canine 
urothelium and from pathologically confirmed cases of UC, using protocols reported 
previously (Poorman et al. 2014; Thomas et al. 2014), with modifications. After 
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deparaffinization with xylene treatment, slides were exposed to Hyaluronidase VIII (45 
U/μL in 250 mM TRIS-buffered saline, pH 7.4, Sigma-Aldrich, St. Louis, MO) at 37°C for 
1 h, followed by a combined collagenase treatment (236 U/μL each of collagenases I and II, 
and 0.4 U/μL of collagenase III (Invitrogen/Life Technologies, Carlsbad)) in HBSS with 2.4 
mM CaCl2 and pretreatment in 80°C sodium thiocyanate for 60 min. Slides were rinsed in 
MQ water, briefly dried, and then immersed in Abbott Protease II solution (Abbott 
Laboratories, Chicago, IL) for 45 min at 37°C. Pretreated slides were dehydrated through an 
ethanol series (70, 90, 100 %), and fluorescent probe (100 ng of each BAC or SureFISH 
probe) in hybridization solution was added. Probes and DNA were codenatured at 80°C for 
5 min, followed by overnight hybridization at 37°C. All hybridization steps and post-
hybridization washes and imaging were as described previously (Thomas et al. 2014). For 
each specimen, probes were visualized by mulitplane fluorescence microscopy, using a 
BioView imaging system built around an Olympus BX61. Probe signals were enumerated in 
>50 cells, each classified as aberrant or nor aberrant, and mean copy number per cell also 
obtained.
FISH of urine sediment
Free-catch urine was mixed with an equal volume of 1× phosphate-buffered saline (PBS) 
and exfoliated cells concentrated by centrifugation (1500 RPM). Urine sediment was rinsed 
in 10 mL 1× PBS. Following centrifugation, supernatant was aspirated to approximately 1 
mL, the cells resuspended and fixed three times in 3:1 methanol/glacial acetic acid. The 
concentrated fixed cell suspension was spotted onto a glass slide for FISH analysis. Slides 
were dehydrated in an ethanol series (70/90/100 %) prior to being heated for 2 min at 65°C, 
transferred to a 37°C slide moat, and treated with pepsin solution for enzyme-induced 
epitope retrieval (Thermo Fisher Scientific, Cheshire, UK) for 30 s to eliminate signal 
background due to protein. Slides were rinsed twice in water and then fixed in 3:1 methanol/
glacial acetic acid for 5 min, rinsed twice in water, and passed through a second dehydration 
series. Hybridization, washes, and imaging were as for the FFPE FISH.
Human oaCGH data
oaCGH-segmented data from 205 human urothelial tumors were accessed via the Cancer 
Genome Atlas (TCGA). Affymetrix Oncoscan FFPE Express Platform (Santa Clara, CA) 
data for an additional 80 cases were downloaded from Gene Expression Omnibus (GEO), 
GSE44323 (Karolchik et al. 2004; Chekaluk et al. 2013). Both data sets were imported and 
merged into a single project using Nexus copy number v7.5 (BioDiscovery, CA).
Humanization of canine oaCGH data for comparative analysis
Canine oaCGH data were recoded into “virtual” human genome format as described 
previously (Thomas et al. 2011; Poorman et al. 2014). Using these recoded coordinates, the 
tumor/reference signal intensity data for each canine data set were reprocessed to output the 
oaCGH profile according to their virtual human chromosome locations. All human and 
humanized canine data were imported into a single experiment in Nexus copy number v7.5 
to allow a direct comparative analysis.
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Generation of call data and probe median values for comparative assessment
Raw data (log2 ratios) for the 80 human oaCGH profiles deposited in GEO and the 31 
canine profiles generated in the current study were analyzed separately to generate species-
specific lists of aggregate genome regions where DNA copy number aberrations (CNAs) 
were evident in >5% of the cohort. The TGCA data set was not associated with raw data 
values and so excluded from this component of the analysis. Regions with contiguous CNAs 
were selected, and the probe median values for each region calculated. Overlap analysis of 
the raw data sets was then performed to isolate regions of sequence similarity that have 
shared aberrations between canine and human data sets. The probe median values for each 
aggregate region for human and canine data were calculated and used to visualize the data as 
concentric Circos plots.
Isolation of regions of overlapping copy number aberration
For isolating regions of CNA shared between human and dog, two input files were created 
for each species: a reference file and a file containing aberration call data. The reference file 
contained syntenic regions of canine and human chromosomes, where each syntenic region 
was indexed using a “link ID” to identify the region throughout aberration analysis. The 
intersect option in Bedtools was used to first find intersecting regions between the aberration 
call data and the reference file for both the dog and human, using a threshold of 1 Mb 
(Quinlan and Hall 2010). The output was a list of overlapping aberrant regions between the 
canine and human data sets as mapped to the reference file. These aberrant regions were 
then matched to the respective link IDs between the two organisms, yielding a set of 
syntenic genomic regions sharing copy number loss or gain. Finally, overlapping link IDs 
were mapped to chromosomal regions with aberration calls, and the frequency of the 
specific aberration per species was calculated. Output data from the final step were merged 
to create a single file referenced by the link ID. Following this unsupervised analysis, the 
process was repeated to target seven a priori human bladder cancer-associated genes: 
PPARG, EGFR, CCND1, MDM2, E2F3, CDKN2A, and RB1 (The Cancer Genome Atlas 
Research Network 2014), to provide verification that these genes also play a role in canine 
UC and suggest a shared pathogenesis.
Statistical validation of the gene list
Regions of conserved copy number aberrations between dog and human were extracted, 
ranked (using R) independently for each organism (based on the frequency) giving priority 
to regions of higher frequency, and validated by calculating the joint probability. For regions 
that tied for the same rank, the ties.method argument of R's rank function was used (R 
Development Team 2010). After calculating the individual ranks for human and dog 
aberrations, the maximum rank between dogs and humans was calculated, focusing on 
regions ranked highest in both species. The probability of the ranks for both gains and losses 
for each organism was calculated and the joint probability derived by multiplying the 
probabilities across both species. Regions with a nominally significant joint probability 
(<0.05) were further assessed.
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Comparative pathologic staging analysis
Comparative analysis was performed using all human (n=285) and canine (n=31) samples 
included in the genome-wide copy number analysis. Canine staging, performed as described 
above, resulted in two tumor groups: group A—Tis and T1, representing non-muscle 
invasive tumors, and group B—T2 and T3, representing muscle invasive tumors. Human 
cases were similarly grouped to allow a comparative analysis of the frequencies of CNAs 
identified across the two groups.
Results
Canine UC biopsies show recurrent DNA copy number aberrations
oaCGH data of DNA isolated from canine UC biopsy specimens revealed that all cases 
presented with numerous recurrent CNAs. Representative genome-wide profiles copy 
number are provided in Fig. 1. In all cases, the CNAs detected were primarily either whole 
chromosome or large segmental aneuploidy. In addition, there were one or more 
chromothriptic-like events detected in 74% (23/31) of patients involving 21 chromosomes. 
A chromothriptic-like event was defined as a cluster of sub-chromosomal regions showing 
alternating copy number gains and losses (Cai et al. 2014). An example of chromothriptic 
events in a single patient is shown in Fig. 2. While most occurred sporadically throughout 
the genome, chromothriptic-like events of CFA 36 were evident in almost 30% of the 
cohort, with involvement of CFA 10 and 16 at 16% and 13 %, respectively, and CFA 4 and 
7 approaching 10% (Fig. 3). Assessment of the evolutionarily conserved chromosome 
segments (ECCS) of these five chromosome segments in the human data indicated that 
while chromothriptic-like events in the ECCS shared with CFA 36 were evident in only 1% 
of cases, such events involving genome regions conserved with CFA4, 7, 10, and 16 were 
detected in 5–7% of cases.
FASST2-processed oaCGH data were compiled into two penetrance plots representing the 
frequencies of called aberrations detected among the DNA samples derived from the fresh 
frozen and fixed tissue specimens (data not shown). Evaluation of the two data sets using the 
“compare” tool of Nexus indicated a high degree of concordance of the specimen type; only 
six aberrations >100 kb in size differed significantly in their frequencies between the two 
sample types. The size of these six regions ranged from 103–330 kb (mean=200 kb) and 
totaled just 1.2 Mb of the genome. With a high degree of concordance between the two 
specimen types, a penetrance plot representing aberration frequencies of all 31 cases of 
canine UC was generated (Fig. 4).
The highest frequency CNAs (>75% of cases) involved large segmented regions of CFA 13 
(gain), 19 (loss), and 36 (gain) (Fig. 4). A second tier of recurrent copy number changes 
(frequency >33 %) was evident as copy number loss of regions of CFA 2, 5, 6, 10, 12, 26, 
27, 28, and X and copy number gains involving regions of CFA 2, 4, 5, 6, 7, 10, 14, 17, 20, 
23, 24, 30, 31, 35, 38, and X. A 1-Mb region located in CFA 8q12 represented a segment of 
the canine genome where no detectable copy changes were evident across the cohort and 
may thus be regarded as an indicator of copy number neutrality for assessment of ploidy 
status. Several highly penetrant gains or losses also exhibited subtle copy number changes in 
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the opposing direction. To develop the most sensitive FISH-based assay designed to detect 
and quantify single loci, regions for probe selection were therefore based on those with 
unidirectional CNAs. The peaks of unidirectional aberration on CFA 13, 19, and 36 had 
frequencies of 96.77% gain, 77.42% loss, and 83.87% gain, respectively (Table 3). 
Evaluation of individual cases indicated that a region of CFA 36 was the most notably 
aberrant with Log2 ratios approaching 5.0 in several cases, suggesting genomic 
amplification.
FISH analysis of FFPE tumor biopsies and urine sediment allows direct visualization of 
urothelial cell copy number status
FISH analysis was performed in 5 μm sections of FFPE non-neoplastic (control) canine 
bladder specimens (n= 5). Currently, SureFISH probes are only available in three colors, 
limiting our analysis to only the aberrant target regions on CFA 13, 19, and 36. There was 
high concordance between data obtained from BAC and SureFISH probes; though the 
SureFISH probes were cleaner (had no visible background signal), had reduced variation 
and a marginally higher mean copy number (Fig. 5a). It is apparent from these data that the 
mean copy number of all probes tested was close to n=2 but slightly elevated (n=2.15–2.3). 
In most tissue types, the use of 5 μm sections results in degree of nuclear truncation, leading 
to a mean copy number of n<2. The elevated mean values in bladder epithelium are to be 
expected due to the presence of binucleate and/or tetraploid transitional epithelial cells, 
common even in healthy urothelium (Sahrief et al. 1980).
Both probe sets were used to assess copy number status of the target loci in cells obtained 
from FFPE UC tumor biopsies (n=5) previously interrogated by oaCGH (Fig. 5b). In each 
case, the data confirmed copy number gain of CFA 13 and 36 and loss of CFA 19 as 
recurrent features, with subtle differences in enumeration between BAC and SureFISH 
probes. In individual cells, the locus on CFA 36 was often detected as >8 copies/cell, and the 
mean of all individual patient means was ∼4.7. CFA 13 displayed more conservative copy 
number gains (mean=∼3.72), and CFA 19 was present in one to three copies (mean=∼2.2), 
depending on genome ploidy (Fig. 5b). The data from BAC and SureFISH probe sets were 
highly effective as a means to acquire enumeration data for all target loci. When used to 
probe transitional cells recovered from the urine sediment of UC patients (n=24), each case 
revealed the presence of one or more of the three target aberrations. The distribution of the 
mean copy numbers derived for each FISH probe along with the combined mean of all cases 
is presented in Fig. 5c, demonstrating the recurrent gain of CFA 13 and 36 and loss of CFA 
19 detected by both BAC and SureFISH probes.
Copy number changes in canine UC—an aid to diagnosis
Analysis of DNA samples from pathologically verified non-neoplastic DNA samples 
(n=100) indicated normal copy number status (n=2) for each of CFA 13, 19, and 36. As 
such, the sensitivity, specificity, percent correctly classified, and the AUC values (with 95% 
CI) for each of the three regions were calculated, based on their aberration frequency in 
confirmed canine UC and the lack of detectable aberration in 100 non-neoplastic tissues. 
The measures of association and potential predictive performance calculated for each of 
three aberrations are presented in Table 4. To evaluate the potential predictive power of a 
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multivariate model (using up to all three regions together, with gain and loss information for 
all three regions included), a decision tree model was constructed. With or without cross-
validation, the best tree only had a single variable included, copy number gain of CFA 13. 
This was the best model and adding the additional variables neither improved nor weakened 
the model. In addition, if two or more of these three aberrations are detected in cells from a 
urinary tract specimen, the sensitivity and specificity to indicate the presence of neoplasm is 
extremely high (>99 %, based on the data set evaluated).
Canine and human urothelial tumors share copy number aberrations
The segmented canine oaCGH data were humanized to allow direct gross genome-wide 
comparison of CNA penetrance with accessible human segmented data (Fig. 6). While the 
general directional pattern of CNA penetrance across the genomes of both species was 
similar, segment penetrance exceeding 33% was rarely seen across the large (n=285) human 
cohort, in line with what has been reported previously (Karolchik et al. 2004; Chekaluk et al. 
2013). However, the high penetrance of the gains of CFA 13 and 36 and loss of CFA 19 in 
canine UC resulted in correspondingly high-frequency regions of penetrance on HSA 2, 4, 
and 8 when presented in their pseudo-human format (Fig. 6b). Copy number aberrations 
along HSA 2p are evident in cases of human UC at about 20% loss and 4% gain (Fig. 6b 
(i)). These events are consistent with changes observed in the canine genome. However, in 
HSA 2q, the extent of the CNAs in regions shared with the dog differs. Along much of the 
length of HSA 2q, the frequencies of copy number gain and loss are comparable (∼10 %) 
until 2q32.2, distal to which there is a gradual decline in the frequency of gain and a 
concomitant increase in frequency of loss, resulting in a gain/loss frequency of 5/20% by the 
telomeric end of HSA 2q. In the humanized canine data, the proximal region of 2q 
resembles that observed in human UC, but a 40-Mb region within 2q12–2q32.2 (HSA 
2:114–154 Mb) is lost in 77% of canine patients. Adjoining and immediately distal to this 
region (HSA 2q23.3–32.2) is a 36-Mb (HSA 2:154–190 Mb) span of copy number gain 
present in ∼83% of cases. This alternating CNA event spans 76 Mb of HSA 2q and is the 
result of shared conserved chromosome segments with the two highly penetrant CNAs we 
identified in canine UC: loss of CFA 19 (distal, 33 Mb of the chromosome) and gain of CFA 
36.
Low-level CNAs along the length of HSA 4 impact the full length of the chromosome in 
human UC (∼8% gain and ∼14% loss), as is largely the case with the humanized canine 
data (Fig. 6b (ii)). However, the canine data demonstrate that the highly penetrant gain of 
CFA 13 is represented by a 97% gain of HSA 4p14–q13.3 (4:41–75 Mb), while the loss 
observed at 4q26–q31.21 (4:121–144 Mb) is due to the highly penetrant loss of CFA 19 
(proximal, 22 Mb of the chromosome).
In human UC, HSA 8p shows a DNA copy number loss in ∼27% spanning 8p23.3–8p12, 
which reduced to ∼13% within 8p12–8p11.1 (Fig. 6b (iii)). A subtle gain (4 %) along 8p 
was noted, with the exception of 8p12– 8p11.1, where the frequency of gain increased to 17 
%. A similar pattern was evident in the canine data. In human UC, 8q is subject to a gain in 
∼25% of cases at 8q11.1, but this frequency increases along the length of the q-arm so that 
by 8q22.1, the gain is seen in 34% of cases. The canine data demonstrate CNA frequencies 
Shapiro et al. Page 10













of 10% gain and 4% loss across 8q11–8q22.1, but 97% gain and 0% loss between 8q22.1 
and 8q24.3 (the final 40 Mb of 8q). This highly penetrant gain of 8q in humanized data is 
due to the conserved segment shared with CFA 13.
To quantify the data and facilitate direct comparison of aligned shared genomic CNAs, a 
higher resolution comparative assessment was conducted using informatics analysis of 
genomic sequence based on syntenic regions of both genomes. Gains and losses were 
assessed separately. Shared region lengths were generated from a data-driven approach, 
ensuring that the novel observations made were compelled by the actual data and not 
influenced by prior knowledge. The first step of the informatics analysis was to find 
intersecting regions between the aberration call data and the reference file for both the dog 
and human, using a threshold of 1 Mb. (Quinlan and Hall 2010). During the subsequent 
steps of the informatics approach, the shared regions are systematically reduced in size to 
define those where aberrations are shared between canine and human samples. With this 
process, a total of 2729 shared copy number gains and 2057 shared copy number losses were 
identified. For both shared gains and losses, 19 and 22 %, respectively, had a joint-rank 
probability of ≤0.05. In both cases, approximately 75% of all shared regions were small at 
<100 kb in size. However, for joint gains, 19% had a length of 100 kb and only 2% were 
>100 kb. For the losses, ∼1 and 25% of the shared loss regions had a length of 100 and 
>100 kb, respectively.
Details of the top nine regions of shared rank across both human and canine UC are 
presented in Table 5 and visualized as concentric Circos plots in Fig. 7. The highest ranked 
regions of genomic overlap shared between canine and human UC cases included copy 
number gains of CFA 13/HSA 8 in 97/52% of patients, respectively (Table 5). The specific 
region of overlap derived from our comparative approach resulted in a segment of HSA 8 
that was just 3 kb in size and segment of CFA 13 that was 17.9 kb. This overlapping region 
had a joint-rank probability of 4.5× 10−7 and indicates a highly significant role in UC for 
both dog and human. Within this shared region is the gene polyadenylate-binding protein 1 
(PABPC1; HSA 8:101,698,044–101,735,037).
Additional significant joint-ranked regions (p<0.05) were further evaluated to determine if 
specific genes associated with CNAs in human UC were also evident in canine UC. Shared 
gains of S100A9, S100A8, and ID1 and shared loss of CDKN2A were identified by our 
pipeline, supporting this data-driven comparative analysis. In both the data-driven and a 
priori comparative analyses, the region surrounding HSA 8:101 Mb/CFA 13:54 Mb 
contained the highest ranked gene in both human and canine UC, PABPC1.
To further assess the potential significance of CNA regions shared between human and 
canine UC samples, gene ontology (GO) analysis was performed using the Protein Analysis 
Through Evolutionary Relationships (PANTHER) classification system (Thomas et al. 
2003a, b). PANTHER was used to cluster the genes from the ranked list of amplifications 
and deletions into known GO components. While the number of genes was large, GO 
analyses highlighted three major gene categories as numerically aberrant in both canine and 
human cohorts: metabolic processes (GO:008152), cellular processes (GO:0009987), and 
biological regulation (GO:0065007) (SOM Fig. 1).
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Canine tumors were staged independently by human and veterinary pathologists with very 
strong agreement (r=0.85) (Table 1), suggesting a high degree of shared histopathologic 
presentation between canine and human UC. Tumors were staged only to the extent of the 
biopsy and so in instances where no muscularis was evident, the highest stage possible was 
T1. When lamina propria was scant or absent, tumors were noted simply as “carcinoma.” 
When assessed by human pathologists, 25.8% (8/31) of canine UC tumors were classified as 
stage Tis, with 51.6% (16/31), 16.1% (5/31), and 6.5% (2/31) as T1, T2, and T3, 
respectively. When assessed by a veterinary pathologists, 48.4% (15/31) were classified as 
carcinoma, with 29% (9/31), 16.1% (5/31), and 6.5% (2/31) classified as T1, T2, and T3, 
respectively. Tumors classified as Tis, T1, and carcinoma were assigned as “non-muscle 
invasive” and the distinct T2 and T3 tumors as “muscle invasive” to facilitate molecular 
comparison.
Following humanization of canine data, stratification of CNAs by invasive phenotype of 
tumor stage was performed to identify shared features (Fig. 8). In spite of low numbers of 
canine cases (which precluded robust statistical analysis), this approach indicted that even at 
earlier stages, canine tumors have much higher levels of CNAs compared with human 
tumors. A striking similarity was the presence of a highly recurrent X chromo-some loss 
(∼50% of cases) in the non-muscle invasive tumors of both human and dog. Shared gains of 
regions of HSA 1q (CFA 7) and HSA 8q (CFA 13) were also present in >35% of human and 
canine tumors reported without muscle invasion. In muscle invasive cases, the frequency 
and size of these chromosomal aberrations increased in both species, along with detection of 
numerous other CNAs. Additionally, the copy number aberration of chromosome X 
switches from a copy number loss in ∼50% of non-muscle invasive tumors to a substantial 
(>50 %) copy number gain in tumors with muscle invasion.
Discussion
Canine UCs exhibit diagnostically relevant copy number aberrations
A major challenge in the management of canine UC is deferred diagnosis. Due to non-
specific clinical symptoms mimicking cystitis and the invasive nature of current diagnostic 
techniques, canine patients with progressive UC often remain undiagnosed for weeks to 
months (Mutsaers et al. 2003). The use of imaging techniques, such as radiography and 
ultrasonography, may identify the presence of abnormal growths in the urinary tract but 
cannot evaluate malignancy. Evaluation of urine sediment by routine cytology can lead to 
mis-diagnosis; neutrophilic infiltration and degranulation due to bacterial cystitis can cause 
altered urothelial morphology, mimicking neoplastic cells. Similarly, neo-plastic cells in 
patients with UC and concurrent bacterial cystitis may elude pathologic detection. As a 
result, biopsy and histopathologic evaluation is considered the “gold standard” of UC 
diagnosis (Mutsaers et al. 2003). Biopsy may be performed by surgery, cystoscopy, or 
traumatic catheterization, all of which are considered invasive procedures. However, 
disturbance of the primary tumor may result in seeding of malignant epithelial cells 
throughout the urinary tract (Anderson et al. 1989). The complications associated with 
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tumor seeding, combined with the invasiveness of biopsy techniques, support the need for 
safer and more efficient diagnostics.
The development of a non-invasive early screening technique to confirm the diagnosis of a 
UC would provide a means to mitigate the seemingly rapid progression of the disease by 
facilitating early therapeutic intervention. The propensity of neoplastic cells to be shed into 
the bladder lumen is one worth exploiting, especially upon examination of the data 
presented in this study. Three particular CNAs, CFA 13 gain, CFA 36 gain, and CFA 19 
loss, were highly recurrent in the canine UC cohort with at least one of these three 
aberrations detected in 100% of canine patients. Detection of transitional cells in the urine 
possessing one or more of these aberrations may therefore be considered highly suspicious 
for UC. Statistical evaluation of our data indicated that, with detection of two or more of 
these aberrations in cells recovered from a canine urinary tract, the sensitivity and specificity 
to indicate neoplasia is extremely high (>99 %). Furthermore, the detection of just the two 
most frequent aneuploidies (gains of CFA 13 and 36) provides an OR of 422.230, a RR of 
33.817, and misclassification of 0. The use of FISH as the gold standard of copy number 
detection and enumeration was shown in this study to be an effective means to identify 
aberrant cells in urine sediment from dogs that presented with a UC. The use of custom 
SureFISH probes provided a more reliable, cleaner and effective alternative to conventional 
genomic (BAC) clone-based FISH probes. This study was based on an evaluation of FFPE 
and urine specimens from UC confirmed and also grossly healthy canine specimens. To 
establish true sensitivity and specificity values for a clinically valuable diagnostic assay, 
similar analyses should be performed using a cohort of canine urine specimens for dogs with 
non-neoplastic diseases of the urinary tract, including dogs presenting with cystitis due to 
infection, bladder stones, bladder polyps, and sterile (inflammatory) cystitis.
Canine UC is of comparative value to human medicine
Previous studies have documented HSA 8q as gained in copy number in 37% of human UC 
patients (Richter et al. 1998). In fact, gain of 8q22 has been identified as the most frequent 
copy number gain in urothelial carcinomas (Van Duin et al. 2005; Heidenblad et al. 2008) 
and is generally associated with poor clinical outcome (Chen et al. 2011). Results obtained 
by combining CNA data from 285 human UC in the present study further supported these 
reports, with 41% of tumors possessing a gain of 8q. The same aberration is also observed in 
our canine data set as gain of syntenic CFA 13, albeit with remarkably high frequency at 
97% of canine UC cases. We propose that the high prevalence of the HSA 8/CFA 13 gain in 
UC highlights its importance in both species and simultaneously suggests an evolutionarily 
conserved molecular pathogenesis in UC tumor development.
Despite the prevalence of the CFA 13 gain in UC, CFA 13 is gained in a number of other 
canine cancers, including sarcomas and carcinomas (Thomas et al. 2003c, 2014; Angstadt et 
al. 2011, 2012; Hedan et al. 2011; Poorman et al. 2014). The frequency of this aberration in 
general canine cancers makes it an unlikely candidate as a single UC-specific marker. 
Nevertheless, the high prevalence of CFA 13 gain in canine cancer suggests it is likely 
fundamental to oncogenesis. Comparative analysis of CFA 13 and HSA 8 indicates that if 
UC indeed shares an evolutionarily conserved mechanism of pathogenesis, genes associated 
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with UC development in both species reside in the proximal half of HSA 8q, the region 
syntenic with CFA 13.
Using joint-rank probabilities to refine alignment of the canine and human genomes reduced 
the extent of the shared regions of HSA 8/CFA 13 to a region of the human genome that 
spans just 3 kb. Within this segment of 8q22.2 is the gene PABPC1, whose protein function 
is to bind the poly-A tail of messenger RNA (mRNA) in the nucleus and shuttle the 
transcript to the cytoplasm for translation (Eliseeva et al. 2013). PABPC1-associated poly-A 
tails stimulate translation and stabilize mRNA in the cytoplasm and increased levels of 
PABPC1 may lead to excessive and oncogenic increases in the mRNA half-lives and thus 
increased potency of even a normal number of transcripts. Previous studies have shown that 
PABPC1 is overexpressed in superficial bladder cancer samples (Chen et al. 2011). Gain of 
the PABPC1 locus in superficial and invasive UCs of both canine and human suggests an 
early and conserved role for the gene in UC progression. In contrast to human UC, the 
majority of canine tumors are invasive (T1–T4) at the time of diagnosis and thus at the time 
specimens are available for genomic analyses. This simple yet stark difference in the clinical 
behavior of canine and human UCs might explain the increased frequency of the aberration 
in dogs compared with humans, while underlining a potential role of PABPC1 in tumor 
progression.
Deletions of HSA 9 are known to be the first genomic alterations associated with human UC 
development (Simoneau et al. 2000). Specifically, loss of HSA 9q characterizes superficial 
bladder tumors and becomes less prevalent with increased tumor stage, while gains of HSA 
8 become more prevalent (Castillo-Martin et al. 2010). The second most significant shared 
region according to our joint-rank probability analyses was a region of HSA 9q/CFA 11 that 
contains CDKN2A. This is a widely studied locus in human cancer research as it codes for 
the p16 tumor suppressor protein, deletion of which has been associated with muscle 
invasive UC in humans, presumably due to the rapid accumulation of mutations 
advantageous to tumor progression (Schulz 2006). In fact, the multicolor FISH-based 
Urovysion® (Abbott Technologies) human bladder cancer diagnostic assay includes 
CDKN2A as one of four regions detected and quantified. Along with focal deletion of 
CDKN2A, a lowered expression of the gene is also observed in human UC samples (Goebell 
and Knowles 2010; The Cancer Genome Atlas Research Network 2014). The canine UC 
genome recapitulates the loss of the CDKN2A locus at a similar frequency (26% vs. human 
38 %), suggesting consequences to expression might also be disrupted in canine UC.
The third- and fourth-ranked regions harbor no apparent coding sequences for genes 
associated with cancer. The fifth-ranked region was located on HSA 1/CFA 7 (a shared 
gain) and is immediately flanked by S100A8 and S100A9. When the ranked region was 
expanded to include the two S100 genes, the aberration penetrance was unchanged. 
S100A8/9 are two damage-associated molecular pattern proteins (DAMPs) released by 
monocytes and neutrophils in response to hypoxia, as occurs in a proliferative tumor 
environment (Bansal et al. 2014). Both S100 proteins have been linked previously to UC 
development, with overexpression being diagnostic for the disease and higher levels 
suggestive of higher-grade tumors (Ebbing et al. 2013). Similarly, overexpression of 
S100A9 is associated with increased proliferation and migration of bladder cancer cell lines 
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(Kim et al. 2011, 2014). The increased frequency of S100 loci gain in dogs (52 %) compared 
with humans (32 %) may be a reflection of the later time of diagnosis and also may 
contribute to the more aggressive tumor phenotype seen in canine patients.
Ranked regions with striking interspecies penetrance disparity include loss of HSA 2/CFA 
19 and gain of HSA 2/CFA 36 (Table 5, regions 6 and 9). In these regions, copy number 
aberrations were observed at high frequency in canine UCs, while in humans, the 
corresponding genomic regions were aberrant only in a small percentage (11 %) of tumors. 
The discrepancy may be a feature of the differential genome architecture of canine and 
human karyotypes, in so far as CFA 36 is a small chromosome but is evolutionary conserved 
as a single 36-Mb segment within the center of HSA 2q (2q23.3–32.2). CFA19 and 36 are 
juxtaposed on syntenic HSA 2 and are each interrupted by breakpoints which have been 
clearly documented in human UC at HSA 2q21 and q31, respectively (Fadl-Elmula 2005). 
Assuming breakpoints are observed in syntenic canine regions, these particular breakpoints 
would represent fragile sites in CFA 19 and 36 predisposed to duplication, deletion, and 
translocation. As canine cells evolve to malignancy, rapidly proliferative cells succumb to 
inherent genomic fragility, resulting in chromosome breaks and copy number aberrations 
(Richards 2001; Ma et al. 2012; Hosseini et al. 2013).
The prevalence of chromothriptic-like events on CFA 36 confirms suspected fragility of the 
chromosome. Chromothripsis, a chromosome-shattering phenomenon, leads to extreme 
genomic rearrangements, deletions, and amplifications within a concentrated chromosomal 
region (Stephens et al. 2011). In canine UC, 74% of tumors showed distinct chromothriptic-
like signatures, most commonly involving CFA 36 (30 %). The amplification of involved 
regions of CFA 36 interrupted by small regional losses, suggests that, at some point in tumor 
evolution, CFA 36 sister chromatids were subjected to numerous double-stranded breaks 
and rejoined imperfectly, leading to the gain of some shattered regions and loss of others. 
Our results of FISH on neo-plastic urothelial cells support this notion, demonstrating 
massive amplification of CFA 36 signal within a small nuclear region. Such chromosomal 
damage may be induced by many means, including mutagenic carcinogens implicated in 
canine and human UC development. The relatively low frequency of chromothriptic-like 
events reported in human UC may be attributed to a more compact human genome, 
composed of 23 chromosome pairs, when compared with the 39 chromosome pairs of the 
canine karyotype, which leads to increased terminal chromosome surface area available for 
damage initiation and rejoining.
The aberrant regions on CFA 19 and 36 contain genes of interest to canine UC. The gene 
LRP1B lies within the breakpoint on CFA 19 (Prazeres et al. 2011). LRP1B possesses tumor 
suppressor function, decreasing the numbers of PDGF and urokinase receptors on the cell 
membrane and halting external proliferation stimuli. Loss of LRP1B is associated with high-
grade urothelial carcinoma in humans and may thus be of equal prognostic significance in 
dogs (Langbein et al. 2002). The fragile site on CFA36 contains the HOXD gene cluster and 
a relevant micro-RNA, miR-10b (Calin et al. 2004). Dysregulated expression of HOX genes 
leads to increased cell proliferation and neoplastic transformation, whereas upregulation of 
miR-10b has been associated with invasive and metastatic abilities in numerous carcinomas, 
including the bladder (Bhatlekar et al. 2014; Xiao et al. 2014).
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Comparative staging analysis allowed comparison of the molecular landscape throughout 
tumor progression. Gains of HSA 1 and 8 and loss of X are the most frequent aberrations in 
non-muscle invasive human tumors, and their syntenic counterparts, CFA 7, 13, and X, are 
similarly aberrant in canine tumors with absence of muscle invasion. These results reaffirm 
the importance of HSA 8/CFA 13 gains, in particular, in UC development. Loss of the X 
chromosome, however, is replaced by a chromosome gain in muscle invasive tumors of both 
canine and human cases. Previous human UC studies have noted a decrease in the number of 
tumors demonstrating an X chromosome monosomy and an increase in polysomy with 
increasing tumor grade (Panani and Roussos 2006). Our results, combined with previous 
findings regarding tumor grade, suggest the involvement of the X chromosome in UC 
muscular invasion.
A major limitation to our staging analyses was the superficial nature of canine biopsies. Due 
to their acquisition via cystoscopy, rarely were all histological layers of the bladder present 
in the biopsied sample. In these cases, tumors were staged using available layers only. 
Therefore, it is likely that numerous canine tumors were at a more advanced stage in vivo 
than we were able to ascertain by biopsy, underrepresenting late-stage tumors and 
potentially obscuring aberration differences among stages. However, the association with X 
chromosome copy number status also adds confidence to the histological definitions 
provided. In future studies, more thorough staging analyses should be performed with more 
complete canine biopsies. Additionally, the same set of veterinary and human pathologists 
did not review the human cases, thereby precluding consistency among all human and 
canine cases
Using PANTHER, the prevalence of genomic aberrations in regions containing critical 
groups of genes highlights the ways in which chromosomal aberrations contribute to 
neoplastic transformation. Our analysis adopted an integrative approach that identified genes 
and pathways that may play a role in UC progression in both canine and human cancers. 
Using the PANTHER classification system and inputting genome-wide CNAs across both 
species, we can identify ontological classes that are over- and under-represented in shared 
genomic regions of canine and human UC samples (SOM Fig. 1). The genes in our analysis 
are enriched across three major ontological components, including signaling pathways in 
metabolic processes, cellular processes, and biological regulation. The role of the pathways 
can now be investigated further by experimental manipulation on both primary UC samples 
and UC cell lines from both canines and humans. Advances of this nature will lead to new 
drug discoveries for UC and/or investigation of already available drugs not currently being 
considered for UC but targeting these same pathways. This type of pathway analyses will be 
strengthened in the future by combining other comparative genomic data from UC tumors 
such as sequence mutation, gene expression, and even epigenetic alterations.
Conclusion
The genomic landscape of canine UC is highly aberrant and of enormous diagnostic 
relevance. The copy number data generated in this study provided the foundations on which 
to develop a diagnostic assay for canine UC with close to 100% sensitivity and specificity. 
Furthermore, the non-invasive nature of a free-catch urine-based assay offers an attractive 
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alternative to current options, which will promote earlier detection and thus maximize 
opportunity for prolonged life. The comparative value of a cross-species approach to cancer 
gene discovery has been demonstrated for UC with the identification of numerous aberrant 
genome intervals shared between human and dog. Through direct comparison of canine and 
human data as well as an informatics approach to highlight the highest ranked changes 
common to both species, we have demonstrated that dogs and humans share major 
cytogenomic aberrations that impact signaling pathways. Further evaluation of such genes 
and pathways as potential therapeutic targets may now be pursued.
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Refer to Web version on PubMed Central for supplementary material.
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AMADID Agilent MicroArray Design Identifier
BAC Bacterial artificial chromosome
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CDKN2A Cyclin-dependent kinase inhibitor 2A
CFA Canis familiaris (also used as a prefix to canine chromosome numbers)
CNA Copy number aberration
DNA Deoxyribonucleic acid
ECCS Evolutionarily conserved chromosome segment
FASST2 Fast Adaptive States Segmentation Technique 2
FFPE Formalin-fixed paraffin embedded
FISH Fluorescence in situ hybridization
GO Gene ontology
H&E Hematoxylin and eosin
HSA Homo sapiens (also used as a prefix to human chromosome numbers)
oaCGH Oligo-array comparative genomic hybridization
OR Odds ratio




TCC Transitional cell carcinoma
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Representative oaCGH profiles of four canine UC cases (TCC10, 15, 28, and 50) from the 
cohort used in the present study. In each case, the oaCGH profiles presents the log2 tumor/
reference ratio on the y-axis and the genome coordinates of the ∼180,000 probes on the 
custom array positioned by chromosome location across all 38 canine autosomes and X 
chromosomes on the x-axis. These four cases illustrate the range of CNAs, represented by 
whole chromosome aneuploidy as well as segmental aneuploidy. Many of the CNAs are 
suggestive of low-level gain/loss, and there are several regions indicative of amplifications. 
For example, the extent of copy number gain for regions of CFA 36 is increased from a gain 
(log2∼1.25) in TCC10 through to a high-level amplification (log2 >4.0) in TCC 15, 28, and 
50. Images output from Biodiscovery's Nexus v7.5
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Representative chromothriptic-like events detected in canine UC. A chromothriptic-like 
event was defined as the detection of alternating regions of copy number gain and loss. In 
each example, regions of copy number gain and loss were determined using the FASST2 
algorithm and are shown with blue and red shading, respectively. The x-axis of each of the 
four chromosomes shown represents the full length of the chromosome, and the y-axis 
represents the log2 ratio of tumor/reference signal
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Frequency of chromothriptic-like events across the canine genome. Data are based on 
oaCGH data of 31 cases of canine UC. Each chromosome was evaluated for the presence of 
chromothriptic-like events and the proportion of canine tumors demonstrating these events 
on each chromosome was calculated. The proportion of dogs with chromothriptic-like 
events on CFA 36 was nearly 30 %, suggesting fragility of this particular chromosome
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Penetrance data of primary canine UC tumors reveal highly recurrent genomic aberrations. a 
Penetrance plot of recurrent CNAs identified within the cohort of 31 canine UC cases. 
Genomic locations are plotted along the x-axis. The y-axis indicates the percentage of the 
corresponding cohort that demonstrated either copy number gain (shown in blue above the 
midline) or loss (shown in red below the midline) of the corresponding chromosome region. 
b Canine ideogram indicating regions of CNA. Blue and red shading to the right and left of 
each chromosome indicates the corresponding regions of the chromosomes exhibiting gain 
and loss, respectively. The horizontal size of the shading corresponds with aberration 
frequency in the population. In (a) and (b), the highest recurrent unidirectional changes are 
shown with arrows (black) on CFA 13, 19, and 36. The green-arrowed region of CFA 8 was 
observed to exhibit a neutral copy number in all 31 cases and so represents a control region
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BAC and SureFISH methods of copy number detection yield comparable results and 
elucidate the extent of copy number alteration in canine UC. Distribution of BAC- and 
SureFISH-derived mean copy number of target regions on CFA 13, 19, and 36 across a 5μm 
FFPE sections of healthy urothelium (n=5), b 5 μm FFPE sections of confirmed UC (n=5), 
and c urine sediment from dogs with confirmed UC (n=24). The mean copy number per 
tumor is shown on the y-axis, and the mean value of all patient means is shown above each 
box and whisker plot
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Visual comparison of “humanized” canine and human UC oaCGH data. a Top, penetrance 
plot of 285 cases of human UC derived from two large public datasets: oaCGH segmented 
data representing 205 human urothelial tumors produced by the Cancer Genome Atlas 
(TCGA) and an additional 80 cases of Affymetrix Oncoscan FFPE Express Platform data 
downloaded from Gene Expression Omnibus (GEO), GSE44323 (Karolchik et al. 2004; 
Chekaluk et al. 2013). Bottom, the penetrance plot of humanized oaCGH data from the 31 
canine UC cases generated as part of the present study (canine data shown in Fig. 4a). b The 
high level of penetrance of DNA copy number gain of CFA 13 is reflected along segments 
of HSA 4 and 8 (ii, iii). The highly penetrant loss of CFA 19 corresponds to loss of regions 
of HSA 2 and 4 (i, ii), and the highly penetrant gain of CFA 36 corresponds to a large region 
of HSA 2 (i), immediately adjacent the region shared with CFA 19
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Key regions of shared CNA shared between human and canine UC. The nine regions from 
Table 5 are depicted as a Circos plot. Orange and green bars in the outer circle represent 
canine and human chromosomes, respectively. DNA copy number losses and gains are 
shown in red and blue, respectively, as a histogram on the inner circle. Color-coded links 
display the nine regions of ranked overlap between canine and human chromosomes
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Comparison of penetrance of CNAs in human and canine (recoded to human) UC when 
evaluated by extent of muscle invasion. Based on histopathologic evaluation, cases of canine 
and human UC were assigned to either group A (no muscle invasion observed) or group B 
(muscle invasion observed). Following CNA detection, penetrance plots for both human 
data and humanized canine data were produced in Nexus copy number and presented. Over 
50% of the cases with non-muscle invasive tumors in both human and dog are associated 
with loss of the X chromosome, while >35% of cases with muscle invasion demonstrate a 
gain of the X chromosome. Human and canine tumors share additional prominent 
aberrations in non-muscle invasive tumors, notably gains of HSA 1q and HSA 8q. In tumors 
with muscle invasion, these aberrations, among others, become more prominent
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Table 3
Frequency of categorical (neutral, loss, or gain) copy number status of the peak unidirectional aberrations on 
CFA 13, 19, and 31 in cases and controls, determined by analysis of DNA samples isolated form biopsy 
specimens of 31 cases of confirmed canine TCC and >100 cases of non-malignant cells
Chromosome Frequency of copy number status
Gain (n>2; %) Loss (n<2; %) Neutral (n=2; %)
TCC “cases” (n=31)
 CFA 13 96.77 0.00 3.23
 CFA 19 0.00 77.42 22.58
 CFA 36 83.87 0.00 16.13
Normal “controls” (n>100)
 CFA 13 0.00 0.00 100.00
 CFA 19 0.00 0.00 100.00
 CFA 36 0.00 0.00 100.00
The expected copy number of all three of these chromosomes is n=2 (neutral), as evident by analysis of cells from healthy dogs. The copy number 
changes detected for CFA 13, 19, and 36 were unidirectional, with CFA 13 and 36 present as additional copies and CFA 19 with reduced copies
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